Broadfin Capital 13F annual report
Broadfin Capital is an investment fund managing more than $403 million ran by Kevin Kotler. There are currently 35 companies in Mr. Kotler’s portfolio. The largest investments include Biodelivery Sciences Intl In and ViewRay, together worth $50.7 million.
$403 million Assets Under Management (AUM)
As of 7th October 2020, Broadfin Capital’s top holding is 4,300,066 shares of Biodelivery Sciences Intl In currently worth over $27.2 million and making up 6.7% of the portfolio value.
In addition, the fund holds 5,574,366 shares of ViewRay worth $23.5 million, whose value grew 21.3% in the past six months.
The third-largest holding is Amarin Plc worth $22.5 million and the next is Biohaven Pharmactl Hldg Co L worth $22.3 million, with 409,338 shares owned.
Currently, Broadfin Capital's portfolio is worth at least $403 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Broadfin Capital
The Broadfin Capital office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Kevin Kotler serves as the Managing Member at Broadfin Capital.
Recent trades
In the most recent 13F filing, Broadfin Capital revealed that it had opened a new position in
STAAR Surgical Co and bought 462,118 shares worth $16.3 million.
This means they effectively own approximately 0.1% of the company.
STAAR Surgical Co makes up
5.2%
of the fund's Health Care sector allocation and has grown its share price by 128.8% in the past year.
The investment fund also strengthened its position in ViewRay by buying
2,573,005 additional shares.
This makes their stake in ViewRay total 5,574,366 shares worth $23.5 million.
ViewRay soared 26.1% in the past year.
On the other hand, there are companies that Broadfin Capital is getting rid of from its portfolio.
Broadfin Capital closed its position in Allergan Plc on 14th February 2020.
It sold the previously owned 96,504 shares for $16.2 million.
Kevin Kotler also disclosed a decreased stake in Amarin Plc by 0.3%.
This leaves the value of the investment at $22.5 million and 1,049,244 shares.
One of the average hedge funds
The two most similar investment funds to Broadfin Capital are M&r Capital Management Inc and Riverstone Group. They manage $403 million and $403 million respectively.
Kevin Kotler investment strategy
Broadfin Capital’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 78.3% of
the total portfolio value.
The fund focuses on investments in the United States as
65.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
9% of the total holdings value.
On the other hand, large-cap stocks make up only 2.9% of the portfolio.
The average market cap of the portfolio companies is close to $1.71 billion.
The complete list of Broadfin Capital trades based on 13F SEC filings
These positions were updated on February 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
Security | Shares Owned | Value | Allocation |
---|---|---|---|
Biodelivery Sciences Intl In |
No change
4,300,066
|
$27,176,000 | 6.75% |
ViewRay, Inc. |
85.73%
5,574,366
|
$23,524,000 | 5.84% |
Amarin Corp. Plc |
33.13%
1,049,244
|
$22,496,000 | 5.59% |
Biohaven Pharmactl Hldg Co L |
23.14%
409,338
|
$22,284,000 | 5.53% |
Alkermes Plc |
315.06%
1,033,500
|
$21,083,000 | 5.24% |
Quotient Ltd. |
225.09%
1,994,183
|
$18,965,000 | 4.71% |
Eiger BioPharmaceuticals, Inc. |
9.58%
1,236,368
|
$18,422,000 | 4.58% |
STAAR Surgical Co. |
Opened
462,118
|
$16,253,000 | 4.04% |
Allergan Plc |
Closed
96,504
|
$16,241,000 | |
Intersect ENT, Inc. |
19.01%
631,023
|
$15,712,000 | 3.90% |
Progenics Pharmaceuticals In |
93.25%
3,060,923
|
$15,580,000 | 3.87% |
NanoString Technologies, Inc. |
401.44%
555,600
|
$15,457,000 | 3.84% |
Iovance Biotherapeutics, Inc. |
52.85%
533,301
|
$14,762,000 | 3.67% |
Dermira Inc |
54.65%
896,334
|
$13,588,000 | 3.37% |
Recro Pharma, Inc. |
27.00%
721,073
|
$13,217,000 | 3.28% |
Nevro Corp. |
Closed
150,510
|
$12,939,000 | |
Wright Med Group N V |
Closed
618,500
|
$12,760,000 | |
Lantheus Holdings, Inc. |
Opened
617,953
|
$12,674,000 | 3.15% |
Vapotherm, Inc. |
Opened
1,003,099
|
$12,198,000 | 3.03% |
AbbVie, Inc. |
Closed
154,500
|
$11,699,000 | |
Sientra, Inc. |
35.71%
1,286,987
|
$11,506,000 | 2.86% |
Vericel Corp. |
161.63%
620,199
|
$10,791,000 | 2.68% |
La Jolla Pharmaceutical Co. |
1,378.23%
2,688,068
|
$10,564,000 | 2.62% |
Alexion Pharmaceuticals, Inc. |
Opened
83,100
|
$8,987,000 | 2.23% |
Sol-Gel Technologies Ltd. |
7.36%
521,819
|
$8,949,000 | 2.22% |
Relmada Therapeutics, Inc. |
Opened
220,724
|
$8,608,000 | 2.14% |
Global Blood Therapeutics In |
Closed
177,016
|
$8,589,000 | |
Aurinia Pharmaceuticals, Inc. |
Opened
400,000
|
$8,104,000 | 2.01% |
Avadel Pharmaceuticals Plc |
66.83%
1,029,012
|
$7,769,000 | 1.93% |
Exicure, Inc. |
17.13%
2,707,851
|
$7,744,000 | 1.92% |
Retrophin, Inc. |
Closed
610,414
|
$7,075,000 | |
Zogenix, Inc. |
2.25%
134,937
|
$7,034,000 | 1.75% |
Strongbridge Biopharma Plc |
Closed
2,578,003
|
$6,161,000 | |
Icu Med Inc |
No change
30,000
|
$5,614,000 | 1.39% |
Exagen, Inc. |
Closed
311,284
|
$4,822,000 | |
Luminex Corp. |
Opened
207,553
|
$4,807,000 | 1.19% |
Catalyst Pharmaceuticals, Inc. |
Closed
880,303
|
$4,674,000 | |
Antares Pharma, Inc. |
Closed
1,336,700
|
$4,471,000 | |
SI-BONE, Inc. |
Closed
223,291
|
$3,946,000 | |
STRATA Skin Sciences, Inc. |
36.94%
1,839,372
|
$3,826,000 | 0.95% |
AnaptysBio, Inc. |
Opened
221,600
|
$3,601,000 | 0.89% |
Aclaris Therapeutics, Inc. |
16.55%
1,888,039
|
$3,568,000 | 0.89% |
GW Pharmaceuticals Plc |
Closed
30,000
|
$3,451,000 | |
Mylan N V |
Opened
150,000
|
$3,015,000 | 0.75% |
ADMA Biologics, Inc. |
Closed
505,900
|
$2,251,000 | |
Heron Therapeutics, Inc. |
8.66%
89,730
|
$2,109,000 | 0.52% |
SCYNEXIS, Inc. |
Opened
2,000,000
|
$1,820,000 | 0.45% |
AMAG Pharmaceuticals, Inc. |
Closed
100,000
|
$1,155,000 | |
Palatin Technologies, Inc. |
No change
1,047,310
|
$819,000 | 0.20% |
No transactions found | |||
Showing first 500 out of 49 holdings |
Hedge funds similar to Broadfin Capital
- Drw Securities
- Wallington Asset Management
- Wishbone Management, L.P.
- Camden National Bank
- Southeast Asset Advisors
- Riverstone Group
- M&r Capital Management Inc
- West Family Investments
- Institute For Wealth Management,
- Investment Management Of Virginia
- Pagnatokarp Partners
- Ma Private Wealth
- Keywise Capital Management (hk) Ltd
- Nine Ten Capital Management